Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase 2 Study of Erivedge(R) (vismodegib) in Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
June 18, 2014 07:00 ET | Source: Curis, Inc.

Curis to Present at the JMP Securities Healthcare Conference

LEXINGTON, Mass., June 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the...
June 05, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces Re-Initiation of Patient Dosing in CUDC-427 Monotherapy Clinical Trial

LEXINGTON, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
June 03, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces Executive Management Transition

-- Ali Fattaey, Ph.D. Promoted to President and Chief Executive Officer -- -- Daniel Passeri Assumes Role of Vice Chairman, Curis Board of Directors and Strategic Advisor -- LEXINGTON, Mass.,...
May 29, 2014 07:00 ET | Source: Curis, Inc.

Curis to Present at the Jefferies 2014 Global Healthcare Conference

LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the...
May 23, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces Abstracts for Its Partnered Programs, Erivedge(R) and Debio 0932 to be Presented at the 2014 ASCO Annual Meeting

LEXINGTON, Mass., May 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced...
May 08, 2014 07:00 ET | Source: Curis, Inc.

Curis Reports First Quarter 2014 Financial Results

LEXINGTON, Mass., May 8, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers, today...
May 01, 2014 07:00 ET | Source: Curis, Inc.

Curis to Release First Quarter 2014 Financial Results and Hold Conference Call on May 8, 2014

LEXINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced...
April 30, 2014 07:00 ET | Source: Curis, Inc.

Curis Announces U.S. Patent Issuance Covering CUDC-907 Composition-of-Matter

LEXINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
April 30, 2014 06:45 ET | Source: Curis, Inc.

Curis to Present at the Deutsche Bank 39th Annual Health Care Conference

LEXINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...